Literature DB >> 2190975

Incidence of gallbladder lithiasis after ceftriaxone treatment.

A Cometta1, S Gallot-Lavallée-Villars, A Iten, L Cantoni, A Anderegg, J J Gonvers, M P Glauser.   

Abstract

Ceftriaxone has potent activity against a broad range of Gram-positive and Gram-negative bacteria. While it is eliminated mainly by the kidney, 10-20% of the drug is eliminated in the bile and ceftriaxone salt precipitates have been described in the gallbladder of animals dosed with ceftriaxone. The purpose of the present study was to investigate the incidence of biliary lithiasis 6 and 12 months after treatment with ceftriaxone and to compare it with that in patients treated with amoxycillin/clavulanate. Biliary ultrasonography was performed at the start of treatment, at 6 months and at 12 months after the beginning of the study. One hundred patients were randomized and 74 were evaluable: 34 were given amoxycillin/clavulanate, 40 ceftriaxone. Gallbladder lithiasis developed in one patient 12 months after the amoxycillin/clavulanate treatment and in none in the ceftriaxone treatment arm. Biliary precipitate during ceftriaxone treatment was not looked for because this phenomenon was not known at the beginning of the study, but gallbladder precipitation that was seen in two patients given ceftriaxone during and at the end of treatment, respectively, resolved spontaneously. In conclusion, ceftriaxone treatment does not appear to lead to gallstone formation more often than an antibiotic that is not eliminated through the bile.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190975     DOI: 10.1093/jac/25.4.689

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Ceftriaxone-associated gallbladder lithiasis in children.

Authors:  A Stabile; P Ferrara; G Marietti; G Maresca
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

2.  Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.

Authors:  Aya Imafuku; Naoki Sawa; Akinari Sekine; Masahiro Kawada; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Noriko Hayami; Jyunichi Hoshino; Yoshifumi Ubara; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2017-10-12       Impact factor: 2.801

3.  Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults.

Authors:  Rika Yoshida; Takeshi Yoshizako; Takashi Katsube; Hajime Kitagaki
Journal:  Jpn J Radiol       Date:  2019-10-25       Impact factor: 2.374

4.  Ceftriaxone-associated Pseudolithiasis in Elderly People: Frequency and Risk Factors.

Authors:  Kiyoshi Hotta; Naohide Hashimura; Masaki Takatsuka; Tomoki Matsuyama; Kouichirou Nakagawa; Tsuneo Yabusako; Shuhei Hosomi; Yasuhiro Fujiwara
Journal:  Intern Med       Date:  2021-12-15       Impact factor: 1.271

5.  Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.

Authors:  Setsuki Tsukagoshi; Kunihiko Ishizawa; Kimitoshi Hirayanagi; Shun Nagamine; Kouki Makioka; Yukio Fujita; Yoshio Ikeda
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.